Pfizer may be the first drugmaker to file for US regulatory authorization for its Covid-19 vaccine, which it says is 95% effective with no serious side effects. This comes right on the heels of news out of Moderna, which says its vaccine also stands at over 94%. With hopes rising that we may see a vaccine in distribution by the end of the year, we speak to Sam Fazeli, Senior Healthcare Analyst at Bloomberg Intelligence, about whether this is truly a cause for excitement.

Image Credit: Shutterstock

Produced by: Dayana Mustak

Presented by: Lyn Mak, Roshan Kanesan, Wong Shou Ning

This and more than 60,000 other podcasts in your hand. Download the all new BFM mobile app.

Categories:  Politics,  Law and Legal Matters,  Health Policy,  Diseases and Conditions,  Mental Health,  Healthy Living,  Fitness,  Science,  Business Analysis,  Trends and Forecasts,  Markets,  Social Issues,  Medical Innovation and Technology,  Investments

Tags:  vaccine,  covid-19,  distribution,  us,  pfizer,  moderna,  astrazeneca,  healthcare,